 |
BioWorld-International-2010-12-08
Medivir Creates Runway for TMC435 with $41M Placement
Medivir Creates Runway for TMC435 with $41M Placement
LONDON – Medivir AB raised €30.8 million (US$41 million) in a private placement that brings in international institutional investors in the lead up to the start of Phase III trials of the lead product, TMC435, a protease inhibitor for treating hepatitis C (HCV) infections. (BioWorld International)